In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intrexon Corp.

www.dna.com

Latest From Intrexon Corp.

Strong Market For Regenerative Medicine Deals Drives Value

Untapped market opportunities for treating and possibly curing underserved diseases have spurred an active deal-making environment in regenerative medicine, according to a new report from Datamonitor Healthcare.

Regenerative Medicine Deals

Synthetic Biology And The Computerization Of Drug Development

Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.

BioPharmaceutical Innovation

Intrexon Buys Tools, Wins Partners

Intrexon’s acquisitions since mid-2014 have given it a shot at solving some high-profile challenges, and have attracted mainstream pharmaceutical partners.

BioPharmaceutical

Device/Diagnostics Quarterly Deal Statistics, Q2 2016

Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.

Deals Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Diversified
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • RheoGene Inc.
  • Genomatix Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Intrexon Corp.
  • Senior Management
  • Randal J Kirk, Chmn. & CEO
    Rick Sterling, CFO
    Thomas D Reed, PhD, CSO
    Andrew J Last, COO
  • Contact Info
  • Intrexon Corp.
    Phone: (301) 556-9900
    20358 Seneca Meadows Parkway
    Germantown, MD 20876
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register